Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTC U1

Next Previous
X
Search
Drug Profile

MTC U1

Alternative Names: MTC-U-1

Latest Information Update: 22 Nov 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotts
  • Class Foot disorder therapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetic foot ulcer; Pressure ulcer; Wounds

Most Recent Events

  • 21 Sep 2022 MTC U1 is available for licensing as of 21 Sep 2022. https://biotts.com/en/our-products/ 3707319
  • 21 Sep 2022 Biotts plans a phase I clinical trial for MTC U1 (Transdermal) (Biotts pipeline, September 2022)
  • 31 Dec 2020 Preclinical trials in Diabetic foot ulcer in Poland (Transdermal), prior to December 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top